Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dedee F Murrell

Showing results (211-220 of 258) with videos related to

Pageof 26
Sort By:
Survey of Ophthalmology|February 19, 2022
Dupilumab-associated ocular manifestations: A review of clinical presentations and managementDuoduo Wu, Benjamin S Daniel, Andre J X Lai, et al.
The Journal of Investigative Dermatology|March 17, 2024
Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized StudyDedee F Murrell, Frédéric Caux, Aikaterini Patsatsi, et al.
JAAD International|August 19, 2021
A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB)Clare L Rogers, Matthew Gibson, Johannes S Kern, et al.
Oncotarget|October 27, 2015
Cytoskeletal protein Flightless I inhibits apoptosis, enhances tumor cell invasion and promotes cutaneous squamous cell carcinoma progressionZlatko Kopecki, Gink N Yang, Jessica E Jackson, et al.
The Journal of Dermatological Treatment|July 11, 2020
International collaborationMitchel P Goldman, Dedee F Murrell, Nawaf Al-Mutairi, et al.
Orphanet Journal of Rare Diseases|July 15, 2022
A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplexJodi Y So, Shivali Fulchand, Christine Y Wong, et al.
The British Journal of Dermatology|June 28, 2025
Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)Melinda Gooderham, Tiago Torres, Shinichi Imafuku, et al.
Muscle & Nerve|June 16, 2011
Epidermolysis bullosa with late-onset muscular dystrophy and plectin deficiencyEppie M Yiu, Alfred Klausegger, Leigh B Waddell, et al.
Veterinary Dermatology|January 4, 2020
Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceusElizabeth C Goodale, Katarina E Varjonen, Catherine A Outerbridge, et al.
Journal of Cell Science|December 21, 2013
Type VII collagen regulates expression of OATP1B3, promotes front-to-rear polarity and increases structural organisation in 3D spheroid cultures of RDEB tumour keratinocytesJasbani H S Dayal, Clare L Cole, Celine Pourreyron, et al.
Pageof 26

Showing results (211-220 of 258) with videos related to

Sort By:
Pageof 26
Survey of Ophthalmology|February 19, 2022
Dupilumab-associated ocular manifestations: A review of clinical presentations and managementDuoduo Wu, Benjamin S Daniel, Andre J X Lai, et al.
The Journal of Investigative Dermatology|March 17, 2024
Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized StudyDedee F Murrell, Frédéric Caux, Aikaterini Patsatsi, et al.
JAAD International|August 19, 2021
A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB)Clare L Rogers, Matthew Gibson, Johannes S Kern, et al.
Oncotarget|October 27, 2015
Cytoskeletal protein Flightless I inhibits apoptosis, enhances tumor cell invasion and promotes cutaneous squamous cell carcinoma progressionZlatko Kopecki, Gink N Yang, Jessica E Jackson, et al.
The Journal of Dermatological Treatment|July 11, 2020
International collaborationMitchel P Goldman, Dedee F Murrell, Nawaf Al-Mutairi, et al.
Orphanet Journal of Rare Diseases|July 15, 2022
A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplexJodi Y So, Shivali Fulchand, Christine Y Wong, et al.
The British Journal of Dermatology|June 28, 2025
Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)Melinda Gooderham, Tiago Torres, Shinichi Imafuku, et al.
Muscle & Nerve|June 16, 2011
Epidermolysis bullosa with late-onset muscular dystrophy and plectin deficiencyEppie M Yiu, Alfred Klausegger, Leigh B Waddell, et al.
Veterinary Dermatology|January 4, 2020
Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceusElizabeth C Goodale, Katarina E Varjonen, Catherine A Outerbridge, et al.
Journal of Cell Science|December 21, 2013
Type VII collagen regulates expression of OATP1B3, promotes front-to-rear polarity and increases structural organisation in 3D spheroid cultures of RDEB tumour keratinocytesJasbani H S Dayal, Clare L Cole, Celine Pourreyron, et al.
Pageof 26